These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 27358756)

  • 41. Acylation of salmon calcitonin modulates in vitro intestinal peptide flux through membrane permeability enhancement.
    Trier S; Linderoth L; Bjerregaard S; Strauss HM; Rahbek UL; Andresen TL
    Eur J Pharm Biopharm; 2015 Oct; 96():329-37. PubMed ID: 26347924
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pathway of oral absorption of heparin with sodium N-[8-(2-hydroxybenzoyl)amino] caprylate.
    Malkov D; Wang HZ; Dinh S; Gomez-Orellana I
    Pharm Res; 2002 Aug; 19(8):1180-4. PubMed ID: 12240944
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intestinal absorptivity-increasing effects of sodium N-[8-(2-hydroxybenzoyl)amino]-caprylate on food-derived bioactive peptide.
    Xu Y; Amakye WK; Xiao G; Liu X; Ren J; Wang M
    Food Chem; 2023 Feb; 401():134059. PubMed ID: 36095999
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intestinal absorption of raltitrexed and evaluation of the effects of absorption enhancers.
    Yu Y; Lu Y; Zhao X; Li X; Yin Z
    Pharmazie; 2013 Sep; 68(9):732-43. PubMed ID: 24147341
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A head-to-head multi-parametric high content analysis of a series of medium chain fatty acid intestinal permeation enhancers in Caco-2 cells.
    Brayden DJ; Gleeson J; Walsh EG
    Eur J Pharm Biopharm; 2014 Nov; 88(3):830-39. PubMed ID: 25460147
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of a Multi-Component Formulation for Intestinal Delivery of a GLP-1/Glucagon Co-agonist Peptide.
    Tran H; Patel PJ; Aburub A; Sperry A; Estwick S; ElSayed MEH; -Mannan AD
    Pharm Res; 2022 Oct; 39(10):2555-2567. PubMed ID: 36050547
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The In Vivo Effect of Transcellular Permeation Enhancers on the Intestinal Permeability of Two Peptide Drugs Enalaprilat and Hexarelin.
    Dahlgren D; Sjöblom M; Hedeland M; Lennernäs H
    Pharmaceutics; 2020 Jan; 12(2):. PubMed ID: 31991924
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist.
    Buckley ST; Bækdal TA; Vegge A; Maarbjerg SJ; Pyke C; Ahnfelt-Rønne J; Madsen KG; Schéele SG; Alanentalo T; Kirk RK; Pedersen BL; Skyggebjerg RB; Benie AJ; Strauss HM; Wahlund PO; Bjerregaard S; Farkas E; Fekete C; Søndergaard FL; Borregaard J; Hartoft-Nielsen ML; Knudsen LB
    Sci Transl Med; 2018 Nov; 10(467):. PubMed ID: 30429357
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term daily oral administration of intestinal permeation enhancers is safe and effective in mice.
    Fein KC; Gleeson JP; Cochran K; Lamson NG; Doerfler R; Melamed JR; Whitehead KA
    Bioeng Transl Med; 2023 Jan; 8(1):e10342. PubMed ID: 36684095
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Absorption-enhancing mechanism of EDTA, caprate, and decanoylcarnitine in Caco-2 cells.
    Tomita M; Hayashi M; Awazu S
    J Pharm Sci; 1996 Jun; 85(6):608-11. PubMed ID: 8773957
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of synergistic permeation enhancers for oral drug delivery.
    Whitehead K; Karr N; Mitragotri S
    J Control Release; 2008 Jun; 128(2):128-33. PubMed ID: 18433909
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In situ and in vivo efficacy of peroral absorption enhancers in rats and correlation to in vitro mechanistic studies.
    Sharma P; Varma MV; Chawla HP; Panchagnula R
    Farmaco; 2005; 60(11-12):874-83. PubMed ID: 16243320
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interaction between Permeation Enhancers and Lipid Bilayers.
    Kang C; Bernaldez M; Stamatis SD; Rose JP; Sun R
    J Phys Chem B; 2024 Feb; 128(7):1668-1679. PubMed ID: 38232311
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of amino acid replacements on in vitro permeation enhancement and cytotoxicity of the intestinal absorption promoter, melittin.
    Maher S; Devocelle M; Ryan S; McClean S; Brayden DJ
    Int J Pharm; 2010 Mar; 387(1-2):154-60. PubMed ID: 20025949
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Permeation characteristics of oligoarginine through intestinal epithelium and its usefulness for intestinal peptide drug delivery.
    Kamei N; Morishita M; Ehara J; Takayama K
    J Control Release; 2008 Oct; 131(2):94-9. PubMed ID: 18692532
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gastrointestinal absorption of heparin by lipidization or coadministration with penetration enhancers.
    Ross BP; Toth I
    Curr Drug Deliv; 2005 Jul; 2(3):277-87. PubMed ID: 16305430
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Graded reversible opening of the rat blood-brain barrier by intracarotid infusion of sodium caprate.
    Preston E; Slinn J; Vinokourov I; Stanimirovic D
    J Neurosci Methods; 2008 Mar; 168(2):443-9. PubMed ID: 18155299
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of sodium caprate on the oral absorptions of danshensu and salvianolic acid B.
    Zhou L; Chow MS; Zuo Z
    Int J Pharm; 2009 Sep; 379(1):109-18. PubMed ID: 19555749
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells.
    Lindmark T; Kimura Y; Artursson P
    J Pharmacol Exp Ther; 1998 Jan; 284(1):362-9. PubMed ID: 9435199
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Absorption enhancement in intestinal epithelial Caco-2 monolayers by sodium caprate: assessment of molecular weight dependence and demonstration of transport routes.
    Lindmark T; Schipper N; Lazorová L; de Boer AG; Artursson P
    J Drug Target; 1998; 5(3):215-23. PubMed ID: 9606011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.